Metabolon and the University of Michigan Announce Agreement
News Oct 24, 2008
The agreement puts in place a number of activities to help progress Metabolon's Prostarix(TM) line of prostate cancer diagnostics including an exclusive license for Metabolon to use prostate cancer aggressitivity markers that were discovered in a collaborative research project between the University of Michigan and Metabolon. This intellectual property will provide the company with a significant competitive advantage in the field of prostate cancer diagnosis and will serve as the basis for Prostarix--which is expected to be launched in late 2009. The agreement also includes a sponsored research agreement with Dr. ArunSreekumar, assistant professor of pathology at the University of Michigan, aimed at a deeper understanding into the role the biomarkers play in the onset of aggressiveness.
"As the second major cause of cancer-related death in the US, prostate cancer creates unique challenges to accurately predict the likelihood of metastasis. Metabolon continues to work with leading researchers like those at the University of Michigan to develop easy-to-use diagnostic tools to better understand aggressiveness and metastatic potential of prostate cancer and to help doctors and patients make critical treatment decisions," explained John Ryals, chief executive at Metabolon.
According to the American Cancer Society, prostate cancer is the most common non-skin cancer found in men in the United States, with one in six men expected to develop the disease during his lifetime. Over 185,000 men are newly diagnosed with prostate cancer each year. Development and progression of the disease are monitored using a prostate specific antigen (PSA) test. Once patients are diagnosed, there are several options: active surveillance, androgen deprivation or radiation therapy, or prostatectomy. These options are based on the likelihood the tumor will become metastatic and spread. However, predicting the likelihood of metastasis has traditionally been very difficult.
Researchers say they have discovered a gene mutation that slows the metabolism of sugar in the gut, giving people who have the mutation a lower risk of diabetes, obesity, heart failure, and even death. The researchers say their finding could provide the basis for drug therapies that could mimic the workings of this gene mutation.
A computer-guided algorithm may help scientists find just the right spot to split a protein and then reassemble it to functionality, according to a new study. Researchers say this could be another step — perhaps even a dance step — toward using chemical and light signals to create new medical treatments and biosensors.READ MORE
8th Edition of International Conference and Exhibition on Separation Techniques
Jul 29 - Jul 30, 2019